RecruitingPhase 1NCT06823609

Phase I Clinical Study of QLS-1304 in the Treatment of Patients With Advanced Malignant Tumors

A Phase I Clinical Study to Evaluate Safety, Tolerability, PK Characteristic and Preliminary Efficacy of QLS-1304 in Patients With Advanced Malignant Tumors

Sponsor

Qilu Pharmaceutical Co., Ltd.

Enrollment

180 participants

Start Date

Mar 6, 2025

Study Type

INTERVENTIONAL

Conditions

Advanced Malignant Tumor

Summary

This study is a multi-center, open label, dose escalation/dose expansion phase I clinical trial aimed at evaluating the safety, tolerability, PK characteristics, and preliminary efficacy characteristics of QLS1304 monotherapy in patients with advanced malignant solid tumors. This study was divided into two stages: dose escalation and dose expansion.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called QLS1304 tablet for people with advanced malignant tumor. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGQLS1304 tablet

QLS1304 monotherapy dose escalation and expansion

Locations(1)

Fudan University Cancer Hospital

Shanghai, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06823609